At a glance
- Originator Novartis
- Class Anti-ischaemics; Antihypertensives
- Mechanism of Action Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 21 Sep 1995 Discontinued-Preclinical for Congestive heart failure in USA (Unknown route)
- 21 Sep 1995 Discontinued-Preclinical for Hypertension in USA (Unknown route)
- 02 Aug 1995 Preclinical development for Congestive heart failure in USA (Unknown route)